EGFR and non-small cell lung carcinoma: Gefitinib is another reversible inhibitor of wild-type and mutant EGFR (Figure 1) indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have del19 or L858R EGFR mutations (AstraZeneca Pharmaceuticals LP, 2015a).